Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD SUMITOMO DAINIPPON PHARMA Co., Ltd

By FDA, JPN

 

Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD SUMITOMO DAINIPPON PHARMA Co., Ltd.

http://www.ds-pharma.com/ir/news/pdf/ene20170831.pdf

More from tokioX :

  1. 💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
  2. 💊SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
  3. 💊Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China
  4. 💊FDA PHARMA today
  5. 💊Dainippon Sumitomo announces the launch of “Seebri ™ Neohaler®” for the treatment of chronic obstructive pulmonary disease (COPD) in the United States  20171020
  6. 💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo
  7. 💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib  20170927